Truist initiated coverage of Madrigal Pharmaceuticals (MDGL) with a Buy rating and $580 price target Madrigal’s lead asset Rezdiffra is the first approved drug for metabolic associated steatohepatitis, which the analyst calls “an underappreciated market.” The firm sees potential for upside over next year as Rezdiffra and MASH gain traction with investors, the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals price target raised to $590 from $500 at Oppenheimer
- Madrigal Pharmaceuticals price target raised to $560 from $460 at B. Riley
- 3 Stocks Showing Strong Buy Signals, According to Technical Analysis
- Madrigal Pharmaceuticals management to meet with B. Riley
- Madrigal Pharmaceuticals assumed with a Buy at H.C. Wainwright